LXEO Stock Forecast & Price Target

Lexeo Therapeutics is attractive because LX2006 has shown a de-risked clinical profile in 17 patients, with no Grade 3+ treatment-related SAEs to date and durable LVMI reductions of 18% at 6 months and 23% at 12 months in patients with abnormal baseline LVMI. The program’s statistically significant neurological signal also strengthens the thesis, as mean mFARS improved versus a matched control cohort (p=0.003) with an annualized difference in progression of 2.3 points, while the company’s $227.6 million cash balance as of 31 March 2026 supports operations into 2028. With FDA alignment on SUNRISE-FA 2 pivotal design as the key catalyst and modeled peak 2032E sales of $580.2 million, the company offers a compelling mix of clinical validation, regulatory visibility, and multiple shots on goal.

Lexeo Therapeutics is a clinical-stage gene therapy company whose outlook is weighed down by significant clinical, regulatory, and manufacturing risk tied to novel AAV-based programs in cardiovascular disease. Human proof-of-concept in FA and PKP2 remains early, and if those signals are not reproduced or safety issues emerge, the company could face trial delays, more capital-intensive pivotal studies, and future equity raises that dilute shareholders; its net cash is modeled at $2.42 NPV/share. Commercially, uptake may be limited by payer and reimbursement hurdles, patient and physician adoption, and competition from more convenient or better-capitalized rivals in cardiomyopathy and Friedreich ataxia.